Medpace (MEDP) Q2 2025 Earnings Transcript

Medpace posted Q2 revenue of $603.3 million, up 14.2% year over year, with EBITDA rising 16.2% to $130.5 million and EPS up to $3.10 from $2.75. Management raised 2025 revenue guidance to $2.42 billion-$2.52 billion and EBITDA guidance to $515 million-$545 million, citing lower cancellations, improved funding, and a shift toward faster-burning metabolic studies that lifted reimbursable costs by 200-300 bps. The company also repurchased 1.75 million shares for $518.5 million in the quarter.

Analysis

MEDP’s quarter reads less like a one-off beat and more like a temporary operating regime shift: execution is being pulled forward by lower cancellations and faster project velocity, while the headline growth is getting amplified by reimbursable pass-throughs. The key second-order effect is that revenue growth is currently understating the quality of demand on a direct-fee basis, but overstating near-term durability if the mix normalizes; that creates a setup where the street can overestimate both 2025 run-rate margin stability and 2026 comparability.

The market is likely missing that this is not simply a stronger bookings environment — it is a timing mismatch between authorizations, backlog conversion, and cash-funded execution. That supports outsized reported revenue and CFO generation now, but it also means the cleanest way for this story to break is not a collapse in RFP flow; it is a reversion in cancellation behavior and/or a cooling in metabolic mix that reduces pass-through intensity over the next 2-4 quarters. If that happens, growth could look much less impressive even if underlying sponsor demand remains okay.

Competitive implications are subtle: CRO peers with lower exposure to investigator-heavy, fast-burn studies may look comparatively more stable on reported revenue, while MEDP’s model will screen as the strongest operator until the mix rolls over. The balance sheet gives management room to keep leaning into buybacks, which can mask some earnings volatility near term, but it also increases the risk that buybacks peak just as the earnings quality peak does. In other words, this is a momentum-positive print with a medium-term normalization risk embedded in the same variables that drove the upside.

Key Decisions for Investors

• Short-dated upside call spread on MEDP into the next print (e.g., 1-2 month tenor, 5-8% OTM long / 15-20% OTM short): express continued momentum in reported numbers while capping premium if the market overprices 2026 durability.
• Pair trade: long MEDP vs short a lower-growth CRO peer with less pass-through leverage (e.g., IQV or CRL) for 3-6 months; thesis is MEDP keeps outperforming on reported growth while peer multiple expansion is capped by weaker execution.
• If long MEDP, hedge with a partial put spread expiring after Q4 results: the main risk window is 2H25 into early 2026 when cancellation normalization or mix reversion could compress the narrative.
• Avoid chasing common equity after a gap-up; prefer scaling only on pullbacks if backlog conversion stays elevated but bookings do not accelerate again in Q3, because the multiple can de-rate quickly once investors focus on 2026 comparables.